We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanoparticle-Delivered siRNA Shrinks Tumors in Mouse Model

By LabMedica International staff writers
Posted on 20 Jul 2015
Print article
Image: TEM (transmission electron micrograph) of a mesoporous silica nanoparticle (Photo courtesy of Wikimedia Commons).
Image: TEM (transmission electron micrograph) of a mesoporous silica nanoparticle (Photo courtesy of Wikimedia Commons).
Cancer researchers employed a nanoparticle delivery system to deliver short interfering RNA (siRNA) that blocked the activity of Twist-related protein 1 (TWIST1), which prevented growth and spread of tumors in a mouse model.

TWIST1, also known as class A basic helix-loop-helix protein 38 (bHLHa38), is a basic helix-loop-helix transcription factor that in humans is encoded by the TWIST1 gene. TWIST1 is a transcription factor whose reactivation in tumors leads to epithelial to mesenchymal transition (EMT), including increased cancer stem cell-like behavior, survival, and invasiveness.

Investigators at the University of California, Los Angeles (USA) used polyethyleneimine-coated mesoporous silica nanoparticles (containing pores with diameters between 2 and 50 nanometers)) to deliver TWIST1 siRNA to mice bearing xenograft tumors. The mice were treated with intravenous injections of the siRNA-nanoparticles weekly for six weeks.

Results published in the June 23, 2015, online edition of the journal Nanomedicine: Nanotechnology, Biology and Medicine revealed that weekly siRNA treatment slowed tumor growth and inhibited not only TWIST1 but also other genes under the control of the epithelial-mesenchymal transition process.

“We were truly surprised by the dramatic effect of delivering TWIST1 siRNA,” said contributing author Dr. Fuyu Tamanoi, professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles. “This demonstrates the effectiveness of our treatment and encourages us to explore further what is happening to the tumor.”

Related Links:

University of California, Los Angeles


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.